123.94
5.24 (4.41%)
| Penutupan Terdahulu | 118.70 |
| Buka | 122.10 |
| Jumlah Dagangan | 980,125 |
| Purata Dagangan (3B) | 994,837 |
| Modal Pasaran | 7,118,461,952 |
| Harga / Pendapatan (P/E Ke hadapan) | 2.50 |
| Harga / Jualan (P/S) | 15.20 |
| Harga / Buku (P/B) | 9.40 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 17 Feb 2026 |
| Margin Keuntungan | -30.57% |
| Margin Operasi (TTM) | -19.39% |
| EPS Cair (TTM) | -2.27 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 24.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 14.09% |
| Nisbah Semasa (MRQ) | 6.49 |
| Aliran Tunai Operasi (OCF TTM) | -45.97 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -17.66 M |
| Pulangan Atas Aset (ROA TTM) | -6.68% |
| Pulangan Atas Ekuiti (ROE TTM) | -20.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Glaukos Corporation | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -1.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.20 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.33% |
| % Dimiliki oleh Institusi | 101.71% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Westfield Capital Management Co Lp | 30 Sep 2025 | 1,231,641 |
| Braidwell Lp | 30 Sep 2025 | 780,164 |
| Brown Capital Management Llc | 30 Sep 2025 | 762,760 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 160.00 (Stifel, 29.10%) | Beli |
| Median | 131.00 (5.70%) | |
| Rendah | 120.00 (JP Morgan, -3.18%) | Beli |
| Purata | 135.33 (9.19%) | |
| Jumlah | 9 Beli | |
| Harga Purata @ Panggilan | 108.80 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 28 Jan 2026 | 131.00 (5.70%) | Beli | 123.94 |
| 02 Jan 2026 | 116.00 (-6.41%) | Beli | 110.72 | |
| Stifel | 22 Jan 2026 | 160.00 (29.09%) | Beli | 125.90 |
| Needham | 14 Jan 2026 | 125.00 (0.86%) | Beli | 104.43 |
| 09 Dec 2025 | 125.00 (0.86%) | Beli | 106.87 | |
| Stephens & Co. | 02 Jan 2026 | 145.00 (16.99%) | Beli | 110.72 |
| UBS | 23 Dec 2025 | 145.00 (16.99%) | Beli | 116.18 |
| Truist Securities | 18 Dec 2025 | 145.00 (16.99%) | Beli | 113.21 |
| Citigroup | 11 Dec 2025 | 125.00 (0.86%) | Beli | 109.23 |
| 30 Oct 2025 | 113.00 (-8.83%) | Beli | 87.80 | |
| JP Morgan | 30 Oct 2025 | 120.00 (-3.18%) | Beli | 87.80 |
| Wells Fargo | 30 Oct 2025 | 122.00 (-1.57%) | Beli | 87.80 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BURNS THOMAS WILLIAM | - | 120.24 | -186,945 | -22,478,267 |
| Jumlah Keseluruhan Kuantiti Bersih | -186,945 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -22,478,267 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 120.24 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BURNS THOMAS WILLIAM | Pegawai | 16 Jan 2026 | Jual automatik (-) | 186,945 | 120.24 | 22,478,267 |
| BURNS THOMAS WILLIAM | Pegawai | 16 Jan 2026 | Pelaksanaan pilihan | 186,945 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 28 Jan 2026 | Pengumuman | Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR |
| 20 Jan 2026 | Pengumuman | Glaukos to Release Fourth Quarter and Full Year 2025 Financial Results after Market Close on February 17 |
| 13 Jan 2026 | Pengumuman | Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance |
| 16 Dec 2025 | Pengumuman | Glaukos Announces Participation in J.P. Morgan Healthcare Conference |
| 03 Nov 2025 | Pengumuman | Glaukos Announces Participation in Upcoming Investor Conferences |
| 29 Oct 2025 | Pengumuman | Glaukos Announces Third Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |